Physician profile
Michael N Castro
NPI 1437180320
$11,078.87
in general payments reported to CMS, 2019-2025
54 companies · $2,314 in 2025
The $2,314 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $728 · 2021: $1,367 · 2022: $1,953 · 2023: $1,429 · 2024: $2,516 · 2025: $2,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,935 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,934.85 |
| Education | $324.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,550.13 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Genzyme Corporation | $1,688.84 | 2019-2025 | |
| Janssen Biotech, INC. | $1,241.51 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $715.82 | 2019-2025 | Otezla, Evenity, Prolia |
| Regeneron Healthcare Solutions, INC. | $522.37 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $400.65 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $379.83 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $301.47 | 2019-2024 | |
| Glaxosmithkline, LLC. | $292.79 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $284.68 | 2020-2025 | Ebglyss, Taltz, Jardiance |
| Sun Pharmaceutical Industries INC. | $281.02 | 2019-2025 | |
| Ucb, INC. | $241.33 | 2019-2025 | Bimzelx |
| Fresenius Kabi USA, LLC | $156.40 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.95 | 2020-2024 | Cyltezo |
| Novo Nordisk INC | $122.15 | 2021-2025 | Ozempic, Wegovy |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.